Dr. Leonard S. Schleifer started Regeneron in his New York City apartment in 1988, eight years after earning his Ph.D. in pharmacology from the University of Virginia, where he also attended medical school.
More than 30 years later, the company was one of the first pharmaceutical companies to develop an effective antibody treatment for COVID-19, an antibody cocktail called REGEN-COV. Please visit UVAToday for the full story and Q&A.